Revision total knee arthroplasty (TKA) for periprosthetic joint infection (PJI) is already a high-stakes endeavor. You’re managing infection, soft tissue compromise, bone loss, patient comorbidities — and now you’re also expected to perfectly thread the needle (sometimes literally) on venous thromboembolism (VTE) prophylaxis.
For years, many surgeons have defaulted to low-molecular-weight heparin (LMWH) in these complex cases. After all, if the patient is high risk, shouldn’t you go “stronger”?
But what if the humble aspirin — yes, that aspirin — quietly outperforms LMWH in this setting?
A recent national database study takes on this very question and delivers results that may surprise even the most die-hard enoxaparin enthusiast.
The Clinical Dilemma: PJI, Spacers, and Clots
Patients undergoing first-stage revision total knee arthroplasty for PJI are not your routine arthroplasty patients.
They’re older (mean age 66 years in this study), medically complex (average Charlson Comorbidity Index 3.2) and often inflamed, immobile, and temporarily limited by antibiotic spacers.
Add prolonged operative time, tissue trauma, and decreased mobility, and you’ve got a perfect storm for VTE.
Despite this, there is no consensus on the optimal chemoprophylaxis agent in this specific population. The debate often boils down to aspirin (ASA): Cheap, easy, oral, well-tolerated or Low-Molecular-Weight Heparin (LMWH): Injectable, potent, traditional “high-risk” option.
But until now, surgeons lacked meaningful comparative data in the PJI revision population.
Study Design: Big Data, Big Question
Investigators queried a large national database from 2016 to 2023 to identify patients undergoing first-stage revision TKA with antibiotic spacer placement for knee PJI.
Key exclusions prior VTE history and use of other prophylactic agents.
Patients were divided into two groups: postoperative day 1 ASA and postoperative day 1 LMWH.
To minimize bias, the authors used propensity score matching, creating two well-balanced cohorts: 10,472 total patients (5,236 ASA and 5,236 LMWH), standardized mean differences < 0.10 across covariates.
Tranexamic acid (TXA) use was nearly identical: 61.2% in ASA and 60.3% in LMWH.
The Results: aAspirin Wins (Yes, Really)
Venous Thromboembolism: ASA: 1.0%, LMWH: 1.6%. P = 0.002. Adjusted odds ratio (aOR) = 0.6. (95% CI: 0.4–0.9).
That’s a 40% reduction in odds of VTE with aspirin in a population considered high risk. Let that sink in.
Postoperative Transfusion: ASA: 6.0%, LMWH: 8.2%. P < 0.001 aOR = 0.8. (95% CI: 0.6–0.9)
Not only fewer clots — but fewer transfusions. In the revision PJI world, bleeding matters.
These cases are already bloody, technically demanding, and physiologically taxing. Anything that reduces transfusion risk without increasing clot risk is clinically meaningful.
Why could aspirin outperform LMWH?
- Bleeding Matters: LMWH is a more potent anticoagulant. Increased bleeding may lead to hematoma formation, transfusion and/or potential delayed mobilization. Bleeding and hematoma are not benign in infected revisions. More bleeding may paradoxically increase complication risk and limit early ambulation — one of our best defenses against VTE.
- Real-World Adherence: Aspirin is oral, easy, no injections, no bruised abdomens. No nursing confusion. By contrast, LMWH requires injection, is more cumbersome and there is potential compliance variability. Aspirin is a win for simplicity.
- The “Good Enough” Hypothesis: Modern arthroplasty protocols already include early mobilization, tranexamic acid (TXA), mechanical prophylaxis and enhanced recovery pathways. In this context, aspirin is not just adequate — it’s optimal.
The Septic Knee Is Not the Primary TKA
It’s worth emphasizing — this is not routine primary arthroplasty. These are infected knees with spacers. The inflammatory burden is different. The physiology is different. The surgical insult is different.
Yet even here, aspirin held its own — and more. This challenges the reflexive assumption that “sicker patient = stronger anticoagulant.”
What about safety?
Critically, this study excluded patients with prior VTE history. So, we are not talking about patients with known hypercoagulable tendencies.
In patients without a VTE history undergoing first-stage revision for PJI ASA was associated with lower VTE rates, it was associated with lower transfusion rates and no signal emerged suggesting harm.
That’s a strong safety narrative.
Cost, Convenience, and Value-Based Care
Aspirin: Pennies per dose, no injections, no need for training.
LMWH: Significantly higher cost, injectable, and more resource-intensive.
In an era of bundled payments and cost-conscious care, if a cheaper option performs as well — or better — that matters.
Especially in complex PJI episodes that are already financially burdensome.
Origin Study Title: Aspirin is Associated with Improved Thromboprophylaxis versus Low-Molecular-Weight Heparin Following Revision Knee Arthroplasty for Periprosthetic Joint Infection
Authors: Julian Wier, M.D.; Pranit Kumaran, B.S.; Sahil S. Telang, B.S.; Mckenzie W. Culler, B.A.; Connor Buchanan, B.S.; Jay R. Lieberman, M.D.; Nathanael D. Heckmann, M.D.